Sarah Tasian, MD

Children’s Hospital of Philadelphia – Chief, Hematologic Malignancies Program;
Perelman School of Medicine, University of Pennsylvania – Associate Professor of Pediatrics (Oncology)

Dr. Tasian is a pediatric oncologist and physician-scientist at the Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine interested in the development of molecularly-targeted therapeutics for children with high-risk leukemias. She specializes in the clinical care of children with hematologic malignancies and is an internationally-recognized expert in pediatric ALL and AML. Her bench-to-bedside and bedside-back-to-bench translational laboratory research program focuses on testing kinase inhibitors and chimeric antigen receptor (CAR) T cell immunotherapies in genetic subsets of childhood ALL and AML. Dr. Tasian has leadership roles in the Children’s Oncology Group ALL and Myeloid Diseases committees and Leukemia Lymphoma Society PedAL/EuPAL consortium. She is the COG Developmental Therapeutics committee Vice-Chair of Biology for Hematologic Malignancies, and leads or co-leads several national or international early-phase clinical trials testing precision medicine therapies in children with high-risk leukemias.

Dr. Tasian earned her medical degree from Baylor College of Medicine, completed her residency in pediatrics at Seattle Children’s Hospital, and fellowship in Pediatric Hematology-Oncology at the University of California San Francisco.